Latest Breakthrough nod goes to Novartis

Share this article:

The FDA announced Tuesday that it has approved the Novartis lung cancer drug Zykadia, or ceritinib (previously known as LDK378).

The approval is for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC), specifically those who were previously treated with Pfizer's Xalkori (crizotinib). Xalkori is the only other approved ALK tyrosine kinase inhibitor but one which (like many molecular targeted drugs) encounters resistance.

The approval is the fourth drug with the FDA's Breakthrough Therapy designation to be approved by the agency.

The drug is also considered an orphan product and is notable for its approval speed: the approval deadline was August 24, four months from now.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.